Rentschler Biopharma will withdraw from the field of cell and gene therapy
Company announces strategic realignment of its global business operations
Rentschler Biopharma SE announced a realignment of its global business operations as part of a long-term strategic shift. As part of this realignment, Rentschler Biopharma will withdraw from the field of cell and gene therapy, ceasing operations at its Stevenage, UK site, and increase its focus on biologics. This decision is embedded in the company’s strategy to adapt to evolving market conditions and client needs, prioritize sustainable growth, and drive innovation.
Rentschler Biopharma SE
“As an innovation leader, we continuously evaluate new approaches to meet the needs of our clients and their patients. The cell and gene therapy market has experienced slower-than-expected growth, with demand across the industry not meeting our expectations. Following a comprehensive strategic review, we are focusing our efforts on areas where we see the greatest demand and potential to create value sustainably. Biologics remain central to our operations, while we continue to evaluate other potential modalities, leveraging our expertise and outstanding track record of delivering the exceptional quality and service our clients rely on,” said Benedikt von Braunmühl, CEO of Rentschler Biopharma. “The dedication and performance of our Stevenage-based team has been exceptional, and I would like to thank everyone for their valuable contributions. We are committed to supporting the affected employees by providing resources and assistance during this transition period”.
In recent years, Rentschler Biopharma has made significant investments to further strengthen its global capabilities and support long-term growth. In 2024, Rentschler Biopharma announced its largest single investment to date at its headquarters in Laupheim, to enhance production efficiency and upgrade the site capabilities. Earlier that year, the new state-of-the-art production line, in Milford, MA in the U.S., became fully operational with four new 2,000 L single-use bioreactors. This investment further advances the company’s capacities and ability to meet the growing demand for biopharmaceuticals, marking the largest investment in Rentschler Biopharma’s more than 150-year history.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.